Form 4: AngioDynamics CEO Awarded Substantial Equity Grants for Long-Term Performance

AngioDynamics Inc. CEO James C. Clemmer was granted 206,253 restricted stock units and 206,253 performance rights, aligning executive compensation with long-term shareholder value.

Summary

• James C. Clemmer, President and CEO of AngioDynamics Inc. (ANGO), was granted 206,253 restricted stock units (RSUs) and 206,253 performance rights on July 16, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock. These RSUs will vest in four equal annual installments, with 25% vesting on July 16, 2026, 2027, 2028, and 2029.
• Each performance right also represents a contingent right to receive one share of Common Stock, with the target number being 206,253 shares.
• The actual number of shares earned from performance rights will range from 0% to 200% of the target, based on total shareholder return relative to a peer group over a three-year performance period.
• There is a potential upward or downward 20% adjustment on the calculated achievement, allowing for a total potential payout of up to 240% of the target number.
• Following these transactions, Mr. Clemmer beneficially owns 887,835 shares of Common Stock and 206,253 performance rights.
• Stephen A. Trowbridge appointed Lawrence T. Weiss as a substitute attorney-in-fact for James C. Clemmer for SEC filing purposes, effective January 20, 2025.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CEO is generally positive as it aligns management's interests with long-term shareholder value and incentivizes performance. While it represents future dilution, it's a standard and often beneficial compensation practice.

Positives

• The granting of 206,253 restricted stock units and 206,253 performance rights to the President and CEO aligns management's interests with long-term shareholder value.
• The performance-based vesting for the performance rights, tied to total shareholder return relative to a peer group, incentivizes strong company performance.
• The potential payout of up to 240% of the target for performance rights offers significant upside for the executive if performance targets are exceeded.

Negatives

• The equity grants, once vested, will result in dilution for existing shareholders, although this is a common form of executive compensation.
• The value of the grants is contingent on future stock price performance and specific performance metrics, meaning the actual realized value could be lower than the target.

Risks

• The value of the restricted stock units and performance rights is subject to the future market price of AngioDynamics Inc. common stock.
• Achievement of the performance rights is contingent on the company's total shareholder return relative to a peer group over a three-year period, meaning the full target may not be achieved if performance is insufficient.
• Any shares that do not vest at the end of the performance period will be forfeited.

Future Outlook

The grants of restricted stock units and performance rights are designed to incentivize long-term performance, with vesting periods extending to July 2029 for RSUs and a three-year performance period for performance rights, aligning the CEO's compensation with future shareholder returns.

Industry Context

This filing reflects a standard practice of executive compensation within publicly traded companies, particularly in the medical technology or healthcare sector, where long-term equity incentives are used to align management interests with shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and performance rights is a common and widely accepted form of long-term incentive compensation for executives in the medical device and broader healthcare industry, similar to practices at companies like Medtronic, Boston Scientific, or Stryker.
• Tying performance rights to Total Shareholder Return (TSR) relative to a peer group is a prevalent best practice in executive compensation, ensuring that compensation is earned based on competitive performance.
• The vesting schedule for RSUs (four equal annual installments) is typical for fostering retention and long-term commitment.
• The potential payout range for performance rights (0% to 200% with a potential 20% adjustment, up to 240%) is within the common range for performance-based equity awards, designed to reward exceptional performance while penalizing underperformance.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and performance rights to James C. Clemmer, the President and CEO, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting of equity awards, but also potential benefit from increased alignment of CEO incentives with shareholder value creation and long-term performance.
• Employees: No direct impact mentioned, but executive compensation practices can indirectly influence overall compensation philosophy.
• Management: James C. Clemmer's compensation structure is significantly tied to the company's future performance and stock price, providing strong incentives.

Next Steps

• Vesting of 25% of restricted stock units on July 16, 2026.
• Vesting of 25% of restricted stock units on July 16, 2027.
• Vesting of 25% of restricted stock units on July 16, 2028.
• Vesting of 25% of restricted stock units on July 16, 2029.
• Determination of performance right payout based on a three-year performance period relative to a peer group.

Key Dates

Keywords

AngioDynamics, ANGO, SEC Form 4, insider transaction, equity grant, restricted stock units, performance rights, executive compensation, CEO, James C. Clemmer, stock ownership, corporate governance